Core Insights - The announcement from Lijun Pharmaceutical (01513) indicates that a total of 194 products from the company have been included in the National Medical Insurance Catalog for 2025, with 92 classified as Category A and 102 as Category B [1] Group 1 - The inclusion of Lijun Pharmaceutical's products in the National Medical Insurance Catalog is significant for the company's market positioning and revenue potential [1] - Notably, the injectable Aripiprazole microspheres have been included in the catalog for the first time through negotiations, which may enhance its market access [1] - The injectable Triptorelin acetate microspheres have received an additional indication, potentially expanding its usage and sales opportunities [1] Group 2 - The injectable Esomeprazole sodium has successfully renewed its contract, ensuring continued reimbursement and market presence [1]

自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 本集團未有產品退出《國家醫保目錄》。本集团前述產品納入《國家醫保目錄》有助於後 續擴大市場及提高藥品可及性，預計未來將對本公司的經營業績產生積極影響。此版《國 家醫保目錄》將於2026年1月1日正式執行，預計不會對本公司当期經營業績產生重大影響。 2 醫保支付標準、醫保報銷細則等相關資訊需以國家醫保局等相關部門公示的資訊為准。公 司產品未來銷售情況受醫藥行業政策變動、市場環境變化等影響，具有一定的不確定性。 敬請廣大投資者審慎決策，注意投資風險。 公司產品納入國家醫保目錄 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」，連同其附屬公 司，統稱「本集團」）自願作出，以告知本公司股東及潛在投資者本集團最新業務更新。 2025年12月7日，國家醫保局、人力資源社會保障部發佈了《國家基本醫療保險、生育保 險和工傷保險藥品目錄（2025年）》（醫保 ...

Core Points - The company, Lizhu Group, announced that it has a total of 194 products included in the National Medical Insurance Directory for 2025, comprising 92 Class A and 102 Class B products [1] - The injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations, while the injectable Triptorelin acetate microspheres have a new indication added, and the injectable Esomeprazole sodium has successfully renewed its contract [1]

Core Viewpoint - The company, Lijun Group, announced that it has successfully included 194 products in the National Medical Insurance Directory for 2025, which includes 92 Class A and 102 Class B products [1] Group 1: Product Inclusion - The injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - The injectable Triptorelin acetate microspheres have a newly added indication [1] - The injectable Esomeprazole sodium has successfully renewed its contract [1]

Core Insights - The company, Lizhu Group, announced that a total of 194 products will be included in the National Medical Insurance Directory by 2025, comprising 92 Class A and 102 Class B products [1] Group 1 - The injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - The injectable Triptorelin acetate microspheres have a newly added indication [1] - The injectable Esomeprazole sodium has successfully renewed its contract [1]

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-075 丽珠医药集团股份有限公司 医保支付标准、医保报销细则等相关信息需以国家医保局等相关部门公示的 信息为准。本公司产品未来销售情况受医药行业政策变动、市场环境变化等影响， 具有一定的不确定性。敬请广大投资者审慎决策，注意投资风险。 特此公告。 关于公司产品纳入国家医保目录的公告 丽珠医药集团股份有限公司董事会 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年本集团共有 194 个产品纳入《国家医保目录》，含甲类 92 个、乙类 102 个。其中：注射用阿立哌唑微球通过谈判首次纳入国家医保目录，注射用醋 酸曲普瑞林微球新增适应症，注射用艾普拉唑钠续约成功，具体详情如下： | 药品名称 | 剂型 | 限定支付范围 | 首次获批 上市时间 | | 谈判情形 | | --- | --- | --- | --- | --- | --- | | 注射用阿立 哌唑微球 | 注射剂 | 无 | 年 2025 | 月 4 | 首次纳入 | | 注射用醋酸 曲普瑞林微 | 注射剂 ...

Core Viewpoint - The announcement by the company indicates that three of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory, which is expected to positively impact future performance [1] Group 1: Product Inclusion - The company has three products included in the new drug directory: injectable aripiprazole microspheres, which is included for the first time; injectable triptorelin acetate microspheres, which has a new indication; and injectable esomeprazole sodium, which has successfully renewed its contract [1] - No products from the company have been removed from the directory, indicating a stable product portfolio [1] Group 2: Market Impact - The inclusion of these products is expected to expand market reach and improve drug accessibility, which will likely have a positive effect on the company's future performance [1] - The new directory will be implemented on January 1, 2026, and is not expected to have a significant impact on the current period's performance [1]

Core Viewpoint - Lijun Group (000513.SZ) announced that it has 194 products included in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's operating performance in the future [1] Group 1: Product Inclusion - The group has 194 products in the National Medical Insurance Directory, including 92 Class A and 102 Class B products [1] - The injectable aripiprazole microsphere has been included in the National Medical Insurance Directory for the first time through negotiations [1] - The injectable triptorelin acetate microsphere has a new indication added, and the injectable esomeprazole sodium has successfully renewed its contract [1] - No products from the group have exited the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of these products in the National Medical Insurance Directory is expected to help expand the market and improve drug accessibility [1] - The new version of the National Medical Insurance Directory will officially take effect on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1]

Group 1 - The company held its 29th meeting of the 11th Board of Directors on December 5, 2025, via telecommunication voting, with all 11 directors present, complying with relevant laws and regulations [1] - The Board approved an adjustment to the expected related party transactions for 2025 with its subsidiary, Zhuhai Lizhu Monoclonal Antibody Biotechnology Co., Ltd., increasing the total expected amount to RMB 166 million, with an additional RMB 37.6 million [2] - The expected amount for energy services was adjusted from RMB 11.8 million to RMB 16 million, and for other labor services from RMB 11.6 million to RMB 45 million, while the amounts for procurement and leasing remained unchanged [2] Group 2 - The proposal involves related party transactions as Health元药业集团股份有限公司 holds a 22.58% stake in Lizhu Monoclonal Antibody, with certain directors abstaining from voting due to conflicts of interest [3] - The proposal was reviewed and approved by the independent directors in a special meeting, with unanimous consent from all independent directors [4] - The voting results showed 7 votes in favor, 0 against, and 0 abstentions [5]

每经AI快讯，丽珠集团（SZ 000513，收盘价：35.78元）12月5日晚间发布公告称，公司第十一届第二 十九次董事会会议于2025年12月5日以通讯表决的方式召开。会议审议了《关于调整公司与丽珠单抗 2025年度持续关连交易预计的议案》等文件。 2025年1至6月份，丽珠集团的营业收入构成为：医药制造业占比100.0%。 截至发稿，丽珠集团市值为323亿元。 每经头条（nbdtoutiao）——秒光、售罄！银行大额存单成稀缺资源，2%以上产品很难抢，有的门槛高 达1000万元！专家：存款利率或长期下行 （记者 曾健辉） ...